DrugPatentWatch Database Preview
Ceftriaxone sodium - Generic Drug Details
What are the generic sources for ceftriaxone sodium and what is the scope of patent protection?
Ceftriaxone sodium
is the generic ingredient in seven branded drugs marketed by Acs Dobfar, Agila Speclts, Aurobindo Pharma Ltd, Bedford, Facta Farma, Fresenius Kabi Usa, Hospira Inc, Lupin, Qilu Pharm Co Ltd, Samson Medcl, Sandoz, Sandoz Inc, Teva, Wockhardt, B Braun, Baxter Hlthcare, Astral, Hikma, Hoffmann La Roche, Roche, Akorn Inc, Cephazone Pharma, Hikma Farmaceutica, and Teva Pharms Usa, and is included in forty-one NDAs. Additional information is available in the individual branded drug profile pages.There are twenty-six drug master file entries for ceftriaxone sodium. Twenty-two suppliers are listed for this compound.
Summary for ceftriaxone sodium
| US Patents: | 0 |
| Tradenames: | 7 |
| Applicants: | 24 |
| NDAs: | 41 |
| Drug Master File Entries: | 26 |
| Suppliers / Packagers: | 22 |
| Bulk Api Vendors: | 74 |
| Clinical Trials: | 15 |
| Patent Applications: | 7,420 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | ceftriaxone sodium at DailyMed |
Recent Clinical Trials for ceftriaxone sodium
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of British Columbia | Early Phase 1 |
| Fayoum University Hospital | Phase 4 |
| Xiangbei Welman Pharmaceutical Co., Ltd | Phase 4 |
Pharmacology for ceftriaxone sodium
| Drug Class | Cephalosporin Antibacterial |
Medical Subject Heading (MeSH) Categories for ceftriaxone sodium
Synonyms for ceftriaxone sodium
| (6R,7R,)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-ylthio)methyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| (6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-ylthio)methyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| (6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-ylthio)methyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| (6R,7R)-7-[[(2E)-2-(2-Amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid Sodium |
| (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| (6R,7R)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-methoxyimino-acetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| (6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7^2-(Z)-(O- |
| (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| (6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-3-(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-[1,2,4]triazin-3-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| (6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-3-(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-[1,2,4]triazin-3-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| (E)-Ceftriaxone Sodium |
| [6R-[6|A,7|A(Z)]]-7-[[(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid sodium salt |
| 104376-79-6 |
| 104376-79-6 (di-hydrochloride salt) |
| 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio)methyl)-, (6R-(6alpha,7beta(Z)))- |
| 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio)methyl)-, (6R,7R)- |
| 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio]methyl]-, (6R,7R)- |
| 7-[2-(2-Amino-thiazol-4-yl)-2-methoxyimino-acetylamino]-3-(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-[1,2,4]triazin-3-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid (Ceftriaxone) |
| 7-[2-(2-Amino-thiazol-4-yl)-2-methoxyimino-acetylamino]-3-(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-[1,2,4]triazin-3-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid(Ceftriaxone) |
| 73384-59-5 |
| 74578-69-1 |
| 74578-69-1 (di-hydrochloride salt, hemiheptahydrate) |
| 75J73V1629 |
| 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid |
| AB1009451 |
| AC-1592 |
| AC-1851 |
| AC1NUIFE |
| AK326214 |
| AKOS015894885 |
| AKOS015960618 |
| AKOS015961150 |
| AN-14520 |
| AN-14762 |
| AN-37256 |
| API0006455 |
| BC203714 |
| BC205730 |
| BDBM50049707 |
| BDBM50103601 |
| Biotrakson |
| C06683 |
| C18H18N8O7S3 |
| Cefatriaxone |
| Cefatriaxone hydrate |
| Cefatriaxone, Antibiotic for Culture Media Use Only |
| Ceftriaxon |
| Ceftriaxona |
| Ceftriaxona [INN-Spanish] |
| ceftriaxone |
| Ceftriaxone (INN) |
| Ceftriaxone (TN) |
| Ceftriaxone [USAN:INN:JAN] |
| Ceftriaxone [USAN:JAN] |
| Ceftriaxone and Dextrose in Duplex Container |
| Ceftriaxone disodium |
| Ceftriaxone free acid |
| Ceftriaxone intravenous |
| Ceftriaxone Sodium [USP] |
| CEFTRIAXONE SODIUM CRUDE |
| Ceftriaxone Sodium E-Isomer |
| Ceftriaxone sodium hydrate |
| Ceftriaxone sodium salt |
| CEFTRIAXONE SODIUM TRIHYDRATE |
| Ceftriaxone, Disodium Salt |
| Ceftriaxone, Disodium Salt, Hemiheptahydrate |
| Ceftriaxonum |
| Ceftriaxonum [INN-Latin] |
| Ceftriazone |
| Cephtriaxone |
| CHEBI:29007 |
| CHEMBL1200995 |
| CHEMBL161 |
| CHEMBL1697718 |
| CS-2948 |
| CTRX |
| D07659 |
| DB01212 |
| DRG-0071 |
| DTXSID0022773 |
| EINECS 277-405-6 |
| EINECS 277-930-0 |
| HY-B0712 |
| I06-164 |
| I06-1763 |
| I06-2130 |
| K250 |
| Longacef |
| LS-150031 |
| LS-150032 |
| MolPort-002-510-741 |
| MolPort-044-724-672 |
| OCTX |
| Ro 13-9904 |
| Ro 13-9904/001 |
| Ro 139904 |
| Ro-13-9904 |
| Rocefin |
| Rocephalin |
| Rocephin |
| Rocephine |
| Rophex |
| SC-57984 |
| SCHEMBL23354 |
| SCHEMBL537013 |
| sodium (6R,7R)-7-((E)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-ylthio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
| Tartriakson |
| UNII-75J73V1629 |
| VAAUVRVFOQPIGI-SPQHTLEESA-N |
| W-104454 |
| X 13-9904 |
| YOBPSXOHCHDCMU-VKZZUTNHSA-M |
| ZINC8584434 |
US Patents and Regulatory Information for ceftriaxone sodium
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lupin | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 065125-003 | Sep 30, 2003 | AP | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| Roche | ROCEPHIN | ceftriaxone sodium | INJECTABLE;INJECTION | 062510-003 | Mar 12, 1985 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Fresenius Kabi Usa | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 065245-004 | Feb 15, 2006 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| B Braun | CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER | ceftriaxone sodium | INJECTABLE;INJECTION | 050796-002 | Apr 20, 2005 | AP | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
| Fresenius Kabi Usa | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 065245-002 | Feb 15, 2006 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Qilu Pharm Co Ltd | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 203702-001 | Jun 29, 2016 | AP | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| Acs Dobfar | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INJECTION | 065329-003 | Jul 24, 2008 | AP | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.